Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors: A Phase II Study.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Calcium; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Gastric cancer; Oesophageal cancer
- Focus Pharmacogenomic; Therapeutic Use
Most Recent Events
- 01 Nov 2012 Biomarkers information updated
- 24 Jan 2012 Planned end date changed from 1 Aug 2012 to 1 Jan 2017 as reported by ClinicalTrials.gov.
- 03 May 2011 Status changed from recruiting to active, no longer recruiting.